Death-associated protein kinase (DAPk), a multi-domain serine/threonine kinase, regulates numerous cell death mechanisms and harbors tumor suppressor functions. In this study, we report that DAPk directly binds and functionally activates pyruvate kinase M2 (PKM2), a key glycolytic enzyme, which contributes to the regulation of cancer cell metabolism. PKM2 was identified as a novel binding partner of DAPk by a yeast two-hybrid screen. This interaction was validated in vitro by enzyme-linked immunosorbent assay using purified proteins and in vivo by co-immunoprecipitation of the two endogenous proteins from cells. In vitro interaction with full-length DAPk resulted in a significant increase in the activity of PKM2. Conversely, a fragment of DAPk harboring only the functional kinase domain (KD) could neither bind PKM2 in cells nor activate it in vitro. Indeed, DAPk failed to phosphorylate PKM2. Notably, transfection of cells, with a truncated DAPk lacking the KD, elevated endogenous PKM2 activity, suggesting that PKM2 activation by DAPk occurs independently of its kinase activity. DAPk-transfected cells displayed changes in glycolytic activity, as reflected by elevated lactate production, whereas glucose uptake remained unaltered. A mild reduction in cell proliferation was detected as well in these transfected cells. Altogether, this work identifies a new role for DAPk as a metabolic regulator, suggesting the concept of direct interactions between a tumor suppressor and a key glycolytic enzyme to limit cell growth. Moreover, the work documents a unique function of DAPk that is independent of its catalytic activity and a novel mechanism to activate PKM2 by protein-protein interaction.
Introduction
Death-associated protein kinase (DAPk), a multidomain serine/threonine kinase, was discovered by an unbiased genetic screen aimed at finding positive mediators of cell death (Deiss et al., 1995) . It has since been characterized as a tumor suppressor protein whose expression is lost in a significant number of human malignancies (Bialik et al., 2004; Gozuacik and Kimchi, 2006; Bialik and Kimchi, 2010) . Loss of DAPk expression is frequently caused by epigenetic silencing through promoter hypermethylation. In addition, a germline mutation in DAPk was found in cases of familial chronic lymphocytic leukemia, in which a single nucleotide change causes a predisposition to chronic lymphocytic leukemia (Raval et al., 2007) .
DAPk is a calcium/calmodulin-activated kinase, which contains a calmodulin-binding domain proximal to the catalytic domain. The multi-domain structure of DAPk also includes a stretch of ankyrin repeats, and a cytoskeleton-binding region, which localize the protein to the actin microfilaments (Cohen et al., 1997; Bialik et al., 2004) (Figure 1a ). Near its C terminus, DAPk harbors a death domain, a six-helical protein-protein interaction module found in various apoptotic proteins Raveh et al., 2000; Goldschneider and Mehlen, 2010) . The tumor-suppressive properties of DAPk have been associated with its role in mediating cell death, as numerous cell-death-triggering signals require DAPk (Bialik and Kimchi, 2006) . These include external signaling initiated by interferon-g, tumor necrosis factor-a, Fas-ligand, transforming growth factor-b as well as internal insults such as oxidative stress, DNA damage and oncogene expression (Bialik and Kimchi, 2006; Eisenberg-Lerner and Kimchi, 2007; Zalckvar et al., 2009) . Interestingly, various modes of programmed cell death have been linked to DAPk, including apoptosis, necrosis and autophagy. Notably the numerous molecular pathways, which have been identified so far to be activated by DAPk, all require phosphorylation of downstream substrates and obligate that DAPk be catalytically active (Bialik and Kimchi, 2006) .
The death domain of DAPk is essential for some of its cell-death-promoting responses (Cohen et al., 1999; Chen et al., 2005; Llambi et al., 2005; Goldschneider and Mehlen, 2010) . We therefore used a yeast twohybrid screen as an unbiased approach to identify proteins that interact with the death domain of DAPk. The screen identified a surprising interacting protein corresponding to the glycolytic enzyme pyruvate kinase (PK).
Pyruvate kinase is encoded by two genes, which give rise to four highly similar isoforms (Mazurek, 2011) . The PKLR gene encodes PKL and PKR through alternative promoter usage yielding two isoform with different N-terminal sequences. The M1 and M2 isoforms are encoded by the PKM gene from two alternatively spliced transcripts varying by only one exon (Clower et al., 2010; David et al., 2010) . Although the M1 isoform is constitutively fully active, the small sequence difference renders the M2 isoform dependent on allosteric activation by fructose biphosphate (FBP), a product of a preceding step in glycolysis (Dombrauckas et al., 2005) . All the other regulatory mechanisms known to date that affect PKM2 activity, such as The DAPk death domain is marked with arrows and the different baits used in the yeast two-hybrid screen are depicted below. The minimal region of PKM, common to all constructs that emerged in the screens, is in orange. The domain encoded by the alternatively spliced exons of PK M1 and M2 variants is displayed in stripes. DAPk and PK schemes are drawn to scale. The domain organization of PKM is colored in a similar way both in the schematic structure and the crystal structure of the protein (PDB accession no. 3ME3). (b) DAPk binds PKM2 in cells. Endogenous DAPk was immunoprecipitated from HeLa CCL2 cell lysates following incubation with latrunculin-B. Immunoprecipitates were immunoblotted with anti-DAPk and anti-PKM1/2 antibodies. Note that endogenous PKM did not co-precipitate in lysates incubated with antibodies targeting an irrelevant protein (control IgG). (c) Direct interaction of purified DAPk and PKM2. Signal intensity in ELISA assay performed with increasing amounts of purified DAPk and equal amounts of PKM2. (d) DAPk interaction with PKM2 is not exclusive to the death domain and does not involve the KD. HEK-293T cells were co-transfected with GFP-tagged PKM2 and FLAG-tagged full-length DAPk, DAPkDDD or the DAPk catalytic domain extending between residues 1 and 305 (KD). Cell lysates and anti-FLAG immunoprecipitates were immunoblotted, and reacted with anti-FLAG and anti-PKM1/2 antibodies.
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I Mor et al phosphorylation of tyrosine residues and proteinprotein interactions, are inhibitory (Hitosugi et al., 2009; Mazurek, 2011) . The M2 isoform is expressed during embryonic development and is turned off in adult somatic cells (Hitosugi et al., 2009; Mazurek, 2011) . A switch in the alternative splicing pattern leads to re-expression of the PKM2 during cancerous transformation and as a consequence, this isoform is almost ubiquitously expressed in tumors and proliferating cell lines (Clower et al., 2010; David et al., 2010) . The initial observation by Warburg (1956) , decades ago that, unlike normal cells, cancer cells secret lactate even in the presence of oxygen, has now been further expanded, leading to the understanding that changes in cell metabolism support cancerous transformation Tennant et al., 2010) . Re-expression of PKM2 has a major role in inducing aerobic glycolysis (Christofk et al., 2008a) , thus, further stressing the importance of studying regulatory processes that modulate PKM2 activity.
Here we report that DAPk physically interacts with PKM2 at high affinity and that this direct interaction promotes PKM2 activity causing increased glycolysis and lactate production concomitant with a mild reduction in proliferation rate. This is an example of a functional link between a tumor suppressor gene and a key enzyme in cancer metabolism and the first documented evidence for an interacting protein that functions as PKM2 activator.
Results
Pyruvate kinase M binds to DAPk DAPk C-terminal region contains a canonical death domain extending between residues 1300 and 1398 (Raveh et al., 2000) (Figure 1a , shown by arrows). Several proteins, which interact with the DAPk death domain, have been identified by using different approaches (Chen et al., 2005; Llambi et al., 2005) . In order to extend the search and identify proteins that interact with DAPk through its death domain in an unbiased manner, we performed several rounds of yeast two-hybrid screens. Baits including the death domain only or the death domain with some flanking sequences ( Figure 1a ) were used to screen a HeLa cell line prey cDNA library. All screens yielded clones encoding large overlapping segments of PKM2 isoform (Figure 1a , arrows indicate the minimal region found in all clones). This region in PKM2, which is almost identical between the M2 and M1 variants, contains the alternatively spliced region, which differs between the two isoforms and participates in FBP binding (Figure 1a, stripes) .
To examine whether DAPk-PKM2 interaction occurs in cells, endogenous DAPk was immunoprecipitated from HeLa CCL2 cells. Endogenous PKM2 co-immunoprecipitated with DAPk but was not pulled down by antibodies directed at an irrelevant protein (Figure 1b) . To determine whether DAPk directly binds PKM2, an enzyme-linked immunosorbent assay (ELISA) was performed. To this end, the FLAG-tagged DAPk and PKM2 were each ectopically expressed in HEK293T cells and affinity-purified from cell extracts (Supplementary Figure 1 ). An ELISA multi-well plate was coated with serial dilutions of purified DAPk (from 10 to 0.63 ng/well) and then incubated with 5 ng of purified PKM2. The relative amount of bound PKM2 was determined by immunodetection with anti-PKM1/2 antibody. This assay clearly demonstrated that fulllength PKM2 can directly interact with full-length DAPk, and that this interaction is linearly proportional to the amount of DAPk in the well (R 2 ¼ 0.995), excluding possible cooperativity in PKM2 binding to DAPk (Figure 1c) .
To further confirm the interaction between DAPk and PKM2 in cells, and to examine the contribution of DAPk death domain and catalytic domain to this interaction, both the proteins were ectopically co-expressed with different tags in HEK293T cells. Full-length DAPk was compared with DAPk lacking the death domain (DAPkDDD) or to the 305 N-terminal residues encoding the DAPk kinase domain (KD). GFP-PKM2 co-precipitated with full-length DAPk, indicating that the two proteins are capable of interacting in cells. Interestingly, PKM2 also co-precipitated with DAPkDDD, indicating that the interaction between the two proteins is not limited to the C-terminal domain, initially used as bait in the yeast two-hybrid screen (Figure 1d ). This was also validated by ELISA in which the binding of PKM2 to purified full-length DAPk was compared with DAPkDDD. In these in vitro quantitative assays, DAPkDDD was able to bind PKM2, yet it yielded lower signal intensity, suggesting that although the death domain contributes to the complex formation, it is not an exclusive domain for the interaction (Supplementary Figure 2) . This is reminiscent of interaction of DAPk with UNC5H2, which was also not abolished by truncation of the DAPk death domain, although this module serves as one of the binding sites (Llambi et al., 2005) . In contrast, almost no PKM2 co-precipitated with the DAPk KD alone, suggesting that this region is not involved in the binding (Figure 1d ).
DAPk binding enhances PKM2 activity
To study whether the interaction between the two proteins affects PK activity, its kinetic parameters were assessed in vitro in the presence and absence of purified DAPk. The activity of PKM2 incubated with DAPk at a 1:1 molar ratio was measured in the presence of different substrate concentrations (Figure 2a ). For baseline control, PKM2 was incubated with cell lysates from mock-transfected cells subjected to the same elution procedure used for DAPk purification. V max and K m values were extrapolated from the plots. Although the K m value did not vary considerably between PKM2 incubated with DAPk and baseline control (0.67 ± 0.10 mM vs 0.71 ± 0.08 mM), V max almost doubled in the presence of DAPk (2.2±0.12 mM/min vs 1.2±0.05 mM/min). This activation was detected at all substrate concentrations, including the estimated physiological concentrations of the substrate phosphoenolpyruvate (B0.1 mM) (Supplementary Table 1 ). The ratio of K cat /K m , a measure of the enzyme efficiency under physiological conditions of low substrate concentration, was also elevated (K cat ¼ 44/s vs 24/s; K cat / K m ¼ 65.7/mM/s vs 33.8/mM/s). Interestingly, DAPk was also able to activate PKM1, purified from rabbit muscle (Supplementary Figure 3a) , similarly showing an elevation in V max (6.8 ± 0.74 mM/min vs 4.7 ± 0.54 mM/min).
To determine whether DAPk activation of PKM2 is a result of transphosphorylation, in vitro kinase assays were performed by incubating GFP-PKM2 with fulllength DAPk purified from HEK293T cells. Although DAPk could phosphorylate a known substrate, MCM3 (Bialik et al., 2008) it did not phosphorylate GFP-PKM2, even when GFP-PKM2 was present at high concentrations (Supplementary Figure 4) . Similarly, DAPk could not phosphorylate PKM1 (data not shown). The lack of transphosphorylation by DAPk was consistent with the inability of the catalytic domain of DAPk to activate PKM in vitro. It was found in this respect that DAPk fragment comprising only the catalytic domain had no effect on PKM2 activity measured at non-limiting substrate concentration (2 mM), whereas the full-length DAPk induced a significant elevation of the PKM2 activity as expected ( Figure 2b ). These results, combined with the finding that the catalytic domain also fails to bind to PKM2 (Figure 1c ), imply that DAPk does not confer its effect on PKM2 by phosphorylation but rather through direct binding. Incubation of PKM2 with the FLAG peptide used for DAPk purification, which is, therefore, present at high amounts in DAPk preparations, did not modify PKM2 activity, testifying to the specificity of its activation by DAPk (Figure 2b) . Notably, the fragment carrying the catalytic domain alone also did not affect the activity of PKM1 (Supplementary Figure 3b) .
Next, we determined the molar ratio at which DAPk can induce activation of PKM. To this end, activity of purified PKM was measured in the presence of decreasing molar ratios of purified DAPk (Figure 2c ) at non-limiting substrate concentration (2 mM). At all molar ratios, PKM2 activity was significantly elevated as compared with PKM2 alone, or to PKM2 incubated with increasing volumes of lysates from mock-transfected cells subjected to the same elution procedure as used for DAPk purification. DAPk activation of PKM2 seems to reach its peak in a 1:2 (PKM2:DAPk) ratio, suggesting that this ratio is sufficient to induce maximal activation of the enzyme. This ratio was also sufficient to induce maximal activation of PKM1 (Supplementary Figure 3c ). Interestingly, DAPk was able to activate PKM2 even at a 4:1 (PKM2:DAPk) molar ratio, though to a lesser extent.
Ectopic expression of catalytically inactive DAPk enhances endogenous PKM2 activity
To determine whether DAPk can promote PKM2 activation in cells independent of its catalytic activity, HEK293T and HeLa JW subline (described in Bialik et al., 2004) were transfected with truncated DAPk lacking the KD (DAPkDKD), or with a structurally irrelevant protein. These cell lines express very low levels of endogenous DAPk, which allowed us to determine the direct effects of the different ectopically expressed mutant proteins. A truncated DAPkDKD was chosen in order to completely abolish kinase activity of DAPk. The activity of endogenous PKM2 was measured in cell extracts. Notably, as DAPk contains a region which Shown is the level of PKM2 activity alone or following incubation with indicated molar ratios of FLAG peptide, GST-tagged recombinant DAPk KD (rec. KD), or purified full-length FLAG-tagged DAPk. (c) DAPk elevates PKM2 activity. Shown is percent elevation in PKM2 activity following incubation with purified full-length FLAGtagged DAPk at increasing molar ratios as compared with activity of PKM2 alone. Eluates from non-transfected cells at equal volumes to eluted DAPk were used as control.
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I Mor et al is responsible for its binding to the cytoskeleton (Figure 1a ), a considerable portion of DAPk in cells is tightly bound to the actin microfilaments (Bialik et al., 2004) . Therefore, to disrupt actin filaments and gently solubilize cytoskeletal protein complexes, cells were incubated with latrunculin-B before protein extraction. Endogenous PKM2 activity was determined in cell lysates containing equal amounts of total protein. In both cell types, PKM2 activity was elevated in lysates from DAPkDKD-transfected cells (Figure 3a) . Immunoblotting verified that total PKM2 protein levels were comparable between the control and DAPk-transfected cells (Figure 3a) . To determine how PKM2 colocalization with DAPk contributes to its activation, levels of endogenous PKM2 activity with and without actin filament disruption were evaluated. In mock-transfected cells, incubation with lantruculin-B had no effect on the activity of endogenous PKM2 measured in cell extracts (Figure 3b , control), indicating that solubilization of cytoskeletal proteins did not change PKM2 extraction efficiency or activity (see also Figure 3c ). Only in DAPkDKDtransfected cells could significantly higher PKM2 activity be detected following incubation with latrunculin-B (Figure 3b, DAPkDKD) . Notably, in the absence of actin solubilization no change in PKM2 activity could be detected (Figure 3b , Àlatrun). This suggests that the PKM2 activated by DAPk is localized to the actin filaments.
Co-immunoprecipitation of HA-tagged DAPk with FLAG-tagged PKM2 indeed demonstrated that disruption of actin filaments by latrunculin-B enriches the level of DAPk-PKM2 complexes in cell extracts without affecting total levels of PKM2 in the extracts (Figure 3c) . We then applied a Triton X-100-based extraction protocol that separates soluble proteins from cytoskeleton-associated proteins. DAPkDKD was expressed in HeLa JW cells, which have undetectable levels of endogenous DAPk. In transfected HeLa JW cells, DAPk was mainly localized to the insoluble, cytoskeletal fraction as expected (Figure 3d ). GFP-PKM2 band densitometry values demonstrated that it was mainly soluble (Figure 3d) . Notably, increased levels of GFP-PKM2 were localized to the cytoskeleton in the DAPkDKD-transfected cells as compared with cells expressing GFP-PKM2 alone while the levels of GFP-PKM2 in the soluble fraction were not changed. In the reciprocal set of experiments, endogenous DAPk was knocked down in A549 cells, which express high levels of this protein. It was found that knockdown of DAPk in A549 cells reduced the levels of endogenous PKM2 localized to the cytoskeletal fraction (Figure 3e) . These experiments suggest the direct recruitment of PKM2 to the cytoskeleton by DAPk.
Glycolytic rate is elevated in DAPk-transfected cells independent of its catalytic activity We determined whether the DAPk effects on PKM2 could eventually result in modification of glycolytic rate. Pyruvate produced by PK, the end product of glycolysis, can be converted to lactate and secreted out of the cells. Thus, lactate levels can be used to assess glycolytic flux. Additionally, as pyruvate is directly converted to lactate, this product closely correlates with PK activity (Hitosugi et al., 2009; Mazurek, 2011) . To validate that PK activity levels correlate with lactate levels, HEK293T cells were transfected with small interfering RNA (siRNA) targeting endogenous PKM2 or with control siRNA. At 72 h after transfection, lactate levels in the medium were determined and normalized to total protein content as a measure of cell mass. Knockdown of PKM2 leads to a 33% reduction in lactate levels in the culture medium (Figure 4a ). To determine whether changes in PKM2 activity, induced by DAPk, result in changes in glycolytic rate, cells were transfected with DAPk, DAPkDKD or mock transfected and incubated in either hypoxic (1% O 2 ) or normoxic conditions for 3.5 h. Both active and inactive DAPk, expressed at similar levels (Figure 4b ), induced elevation in lactate secretion as compared with mock-transfected controls. This elevation was present both in hypoxic and in normoxic conditions. Maintenance of an elevation of cellular ATP levels in DAPk-transfected cells in the presence of mitochondrial complex III inhibitor, antimycin A (Supplementary Figure 5) , also supported the notion that the effect of DAPk on cell metabolism did not involve mitochondrial respiration.
To determine whether elevated lactate production was accompanied by a general increase in glucose metabolism, we first measured glucose uptake in DAPkDKD or mock-transfected cells. Cells were incubated with 100 mM of the fluorescent glucose analog, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) following incubation in Dulbecco's modified Eagle medium containing 5 mM glucose. Fluorescence intensity measured by flow cytometry indicated no difference in glucose uptake in DAPkDKD-transfected cell compared with control cells (Figure 4c, right) . Nevertheless, lactate levels in the medium of the DAPkDKD-transfected cells were elevated by 25% (Figure 4c, left) . Second, increase in lactate production, but not in glucose uptake, was also measured following 2.5 h incubation in Earl's balanced salt solution, which contains glucose as a sole carbon source (5 mM; Supplementary Figure 6 ). This supports the notion that the lactate measured was indeed the product of glucose metabolism.
Finally, we measured whether the activation of PKM2 by DAPk has an effect on cell proliferation by transfecting cells with DAPkDKD or an irrelevant protein. At 24 h post-transfection, cells were counted, re-plated at the same initial number and cultured for additional 48 h. Cell counts were used to calculate the population doubling time. In three independent experiments, DAPkDKD-transfected cells displayed a cumulative decrease of about 30% in cell counts at the end of the experiments. This decrease indicated a significant average of 19 ± 5% increase in doubling time (Figure 4d ; Po0.04, paired Student's t-test). As expected (Bialik et al., 2004) , DAPk lacking the catalytic domain did not induce cell death in these experiments as measured by Trypan blue staining.
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Discussion
Changes in metabolism are a key characteristic of the cancer cell. Oncogenes and tumor suppressors contribute to the regulation of metabolic processes (Yuan and Cantley, 2008; Jones and Thompson, 2009; Mason and Rathmell, 2011) . Discovering the mechanisms which regulate PKM2 activity is, therefore, critical to the understanding of how alterations in cellular metabolism are controlled in cancer cells and whether they display causal effects during the process of tumorigenesis. Interestingly, PKM2 is inhibited by tyrosine phosphorylation (Christofk et al., 2008b) . As activation of tyrosine kinases occurs in response to growth factors DAPk regulates cell metabolism through PKM2 I Mor et al (Christofk et al., 2008b; Yuan and Cantley, 2008) , this suggests that PKM2 can be negatively regulated by oncogenes. Here, we show the other side of the coin and prove that the tumor suppressor DAPk is capable of activating PKM2. Our findings that DAPk binds and activates PKM2 provide new insights into the regulation and function of both proteins. The PKM1/2-DAPk interaction was detected in vitro under conditions in which both proteins were below micromolar concentrations. Binding at such low concentrations suggests high affinity for this protein-protein interaction (Kuriyan and Eisenberg, 2007) . Interestingly, no other PKM binding protein has been demonstrated to enhance its activity (Mazurek, 2011) . The canonical way to activate PKM2 is through allosteric interaction with FBP, which causes a conformational change in the C-terminal region. PKM1 lacks the region that binds to FBP and is constitutively active (Dombrauckas et al., 2005) . In the presence of purified DAPk, both PKM2 and PKM1 were activated as demonstrated by elevated V max . Moreover, although FBP activates PKM2 by enhancing its affinity to the substrate phosphoenolpyruvate, as indicated by reduced K m , without changing the V max (Dombrauckas et al., 2005) , DAPk increased the catalytic rate as indicated by elevated V max , without affecting K m . Elevation of the maximal catalytic rate suggests that under conditions when the enzyme is saturated, the reaction rate is increased. The different effect of DAPk on the kinetics of PKM2 as compared with FBP, as well as its effect on PKM1, suggests that the mechanism involved is different from the conformational change imposed by the allosteric activator, possibly affecting a region in PKM that is common to both M1 and M2 isoforms. Considering the high degree of structural similarity between all four PK isoforms, DAPk activation might extend to all variants. However, the extent of activation could differ between variants as the increase in PKM1 activity was considerably lower than that induced in PKM2. Obviously cell-based experiments are required to determine whether the in vitro measurements also reflect in vivo effects. PKM2 activity is also regulated by its structural organization in tetramers or dimers. In its tetrameric form, PKM2 is physiologically active and leads to elevated lactate production, whereas dissociation into dimers causes the affinity to the substrate to drop below physiological levels and renders the enzyme inactive, leading to accumulation of glycolytic intermediates (Mazurek, 2011) . That activation of PKM2 by DAPk was detected, even at a 4:1 (PKM2:DAPk) molar ratio suggests that one molecule of DAPk could be sufficient to activate a tetramer of PK.
DAPk has two cytoskeleton binding domains that localize it to actin fibers (Bialik et al., 2004) . We show here that ectopic DAPkDKD expression increased, and conversely the knockdown of endogenous DAPk decreased the amount of PKM2 localized to the insoluble protein fraction, consisting of cytoskeletonbound proteins. In addition, actin depolymerization by latrunculin-B was required for efficient extraction of DAPk-PKM2 complexes as well as for detection of PKM2 activation in DAPk-transfected cells. This suggests that the activated fraction of PKM2 localizes to the cytoskeleton as well. As latrunculin-B had no detectable effects on the total extractable levels of PKM2, this fraction should be small, yet sufficient, to contribute to the cellular effects. This could explain why a reduction in PKM2 activity was not detected in DAPk-knockdown cells treated with latrunculin-B, as release of the cytoskeletal fraction of PKM2 activated by endogenous DAPk would dilute it in the soluble PKM2 population. Altogether we suggest that DAPk can only bind and activate a sub-population of PKM2 associated with the cytoskeleton. Multi-protein complexes containing glycolytic proteins are known to be formed in order to increase the flux through consecutive enzymatic reactions, and PK is known to be localized to such glycolytic enzyme complex (Mazurek et al., 2001; Spoden et al., 2008) . Additionally, localization to F-actin has been correlated with activation of other glycolytic enzymes (Real-Hohn et al., 2010) . By residing in the same cellular compartment as PK, DAPk can participate in regulating the glycolytic rate. Pyruvate produced by PK can be transported to the mitochondria to be used in the tricarboxylic acid cycle and respiration, or converted to lactate. Elevated lactate secretion is one of the hallmarks of cancer cells. PKM2 expression favors the elevation of lactate secretion at the expense of mitochondrial respiration . Lactate levels were measured at 72 h after transfection following 2 h incubation in fresh full-conditioned medium. Immunoblotting demonstrates effectiveness of siRNA in reduction of endogenous PKM2 levels (n ¼ 2). (b) DAPk enhances lactate secretion independent of catalytic activity. Lactate levels were measured in conditioned medium from DAPk, DAPkDKD or mock-transfected cells (control) incubated for 3.5 h under hypoxic (1% O 2 ) or normoxic conditions. Lactate levels were normalized to total protein content. DAPk induced elevation in lactate secretion independent of its activity.
Immunoblotting demonstrates similar levels of both DAPk variants expressed. (One of two independent experiments; n ¼ 2. **Po0.01, *Po0.05, Student's t-test). (c) DAPk enhances lactate secretion but not glucose uptake. Lactate levels were measured in medium of DAPkDKD or mock-transfected cells (control) incubated for 2.5 h in Dulbecco's modified Eagle medium containing 5 mM glucose without serum. Left: normalized lactate levels in DAPkDKD-transfected cells presented as percent of lactate in mock-transfected cells. Right: glucose uptake determined by flow cytometry measuring fluorescence following incubation with 100 mM 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG). (d) DAPk reduces cell proliferation. Shown is doubling time of HEK-293T cells transfected with DAPkDKD or irrelevant protein (control) calculated by measuring increase in cell counts 48 h after plating. Results of three independent experiments are presented, triplicate samples in each experiment (*Po0.05 Student's t-test).
DAPk regulates cell metabolism through PKM2 I Mor et al without changing glucose uptake (Christofk et al., 2008a) . Similarly, DAPk overexpression led to an increase in lactate production, although glucose uptake remained unchanged. This suggests that by elevating PK activity, DAPk regulates the utilization of glucose in different pathways, possibly increasing glycolysis at the expense of biosynthetic pathways branching from it, such as the pentose phosphate pathway and amino acid biosynthetic reactions (Deberardinis et al., 2008; Tennant et al., 2010) . As glucose uptake is dependent on membrane glucose transporters, it is highly plausible that activation of PK activity would not change the level of glucose uptake. As biosynthesis of nucleotides, through the pentose phosphate pathway, and of amino acids, is required for cell growth (Deberardinis et al., 2008) , activation of PK by DAPk could potentially impede cellular proliferation. Notably, the correlation between PKM2 activity and cell proliferation is still debated, as inhibition of PKM2 was shown to have both pro-and anti-proliferative effects (Spoden et al., 2008; Hitosugi et al., 2009) . Here expression of inactive DAPk led to a reduction in cell proliferation rate. Regulation of PKM activity and of cell metabolism suggests new arenas for DAPk, both at the functional and mechanistic level. First, DAPk's effects on glycolysis suggest that it has a newly identified biological function as a metabolic regulator, as known for other tumor suppressors (Jones and Thompson, 2009; Mason and Rathmell, 2011) . Second, all the effects induced by DAPk on purified PK and on cell metabolism are independent of its catalytic activity. To date, almost all known DAPk biological functions require phosphorylation of downstream substrates (Bialik and Kimchi, 2006) . Here we report a biological function, which is conferred through direct protein-protein interaction. Through binding to PKM2, DAPk can participate in determination of cell fate under conditions of cellular transformation and adaptation of cancer cells to changes in nutrient supply. It is possible that DAPk metabolic effects contribute to its function as a tumor suppressor in addition to its other cell-death-inducing effects, which depend on the activation of the KD.
Materials and methods
All chemicals and reagents were obtained from Sigma-Aldrich (St Louis, MO, USA), unless indicated otherwise.
Cell culture HEK293T and HeLa JW (described in Bialik et al., 2004) cell lines were cultured as previously described (Bialik et al., 2008) . HeLa CCL2 cells were obtained from the ATCC resource center (http://www.atcc.org). Cells were grown in Dulbecco's modified Eagle medium (Biological Industries, Beit Ha'emek, Israel) containing 25 mM glucose supplemented with 10% fetal calf serum and 2 mM L-glutamine, at 37 1C and 5% CO 2 . Hypoxia was induced by incubating cells at 1% O 2 for indicated times. Plasmids and siRNA were transiently transfected by the calcium phosphate method.
Protein immunoprecipitation and purification
For co-immunoprecipitation of endogenous proteins, HeLa CCL2 cells were incubated with the actin-depolymerization agent latrunculin-B (10 mM; Calbiochem, Darmstadt, Germany) for 30 min before lysis. Cells were lysed with B-buffer (20 mM HEPES, pH 7.6, 100 mM KCl, 0.5 mM EDTA, 0.4% Nonidet P-40, 20% glycerol). Cell lysates, containing 3 mg total protein, were cleared by incubation with protein A beads (1 h, 4 1C; Santa Cruz Biotechnology, Santa Cruz, CA, USA) to prevent nonspecific binding to the beads. Lysates were then incubated with 5 mg anti-DAPk polyclonal rabbit antibody (H-300, Santa Cruz, overnight, 4 1C) or with polyclonal antibody from the same manufacturer directed at an irrelevant protein, which served as negative control. Beads were washed three times with B-buffer and then boiled with denaturing sample loading buffer to free bound proteins. Immunoblotting for DAPk was performed with mouse monoclonal antibodies (D2178, Sigma). Immunoblotting for PKM2 was performed with rabbit anti-PKM1/2 monoclonal antibody (C103A3, Cell Signaling, Danvers, MA, USA) and secondary antibody directed at native rabbit IgG (Sigma).
For co-immunoprecipitation of ectopically expressed tagged proteins, HEK293T were transfected with the indicated plasmids and lysed in B-buffer at 24-48 h after transfection. In cases in which protein association to the cytoskeleton was examined, cells were incubated with latrunculin-B for 30 min before lysis. Precipitation was performed with equal amounts of total protein content as described above with anti-GFP antibodies that were pre-incubated with protein G beads or with anti-FLAG M2 beads (Sigma).
For protein purification, FLAG-tagged full DAPk, DAPkDDD and PKM2 ectopically expressed in HEK293T cells were purified essentially as described elsewhere (Bialik et al., 2008) . For DAPk extraction, cells were incubated with latrunculin-B before lysis. Proteins were subsequently immunoprecipitated from cell lysates by anti-FLAG M2 monoclonal antibodies conjugated to protein G beads (Sigma) as described above. Protein was eluted by incubation of the beads with excess FLAG peptide in Tris-buffered saline at 30 1C for 5 min. Concentration of eluted proteins was determined by comparison of band intensities of known bovine serum albumin concentrations to aliquots of eluted proteins on Gelcode (Bio-Rad Laboratories, Hercules, CA, USA) stained gel.
Enzyme-linked immunosorbent assay
Maxisorp multi-well polystyrene plates (Nunc, Langenselbold, Germany) were incubated with the indicated amount of eluted Flag-tagged DAPk diluted in phosphate-buffered saline (PBS). Wells incubated with equal amount of Flag peptide only or no protein at all were used as negative controls. Plates were washed with PBS with Tween-20 and blocked with 4% bovine serum albumin (Sigma) in PBS and then incubated with eluted Flag-tagged PKM2 in PBS or PBS only. Plates were washed to remove unbound PKM2 and then incubated with rabbit anti-PKM1/2 monoclonal antibody (Cell Signaling) at a 1:300 dilution, washed and incubated with horse radish peroxidaseconjugated goat anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA, USA). Detection was carried out with the horseradish peroxidase substrate 2,2 0 -azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt.
Pyruvate kinase activity assay Pyruvate kinase activity was measured by a lactate dehydrogenase-coupled enzyme assay. PKM2 eluted from cell extracts or rabbit muscle PKM1 (Sigma, P7768) was incubated with eluted DAPk at a 1:1 molar ratio, 0.1 nmol each, in 50 ml reaction buffer (50 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl 2 ) at room temperature to allow binding. After 30 min incubation, reactions were supplemented with 4 mM ADP, 100 mM NADH and 3 U lactate dehydrogenase (Sigma, L2500) and phosphoenolpyruvate at 2 mM or other indicated concentration in a final volume of 200 ml. Reduction in absorbance at 360 nm was measured to determine reaction rate. The effect of purified full-length DAPk, FLAG peptide in the same concentration as in the DAPk preparations, or recombinant GST-tagged human DAPk fragment containing residues 1-365 (SignalChem, Richmond, Canada) on the activity of purified FLAG-tagged PKM2 or rabbit muscle PKM1 was determined. For PK activity in cell extracts, transfected cells were incubated with 20 mM latrunculin-B for 30 min before lysis and 2 mg of total cell extracts were assayed.
Extraction of soluble and insoluble protein fractions
The procedure was performed as described elsewhere (Cohen et al., 1997) . Briefly, HeLa JW cells were co-transfected with GFP-PKM2 and DAPkDKD or a non-coding plasmid as control. A549 cells were transfected with DAPk siRNA or non-targeting siRNA as control (see supplementary information for full details). Soluble proteins were extracted by incubating the plate with MES buffer (50 mM MES, pH 6.8, 2.5 mM EGTA, 2.5 mM MgCl 2 ) with 0.5% Triton X-100 followed by ethanol precipitation. The remaining insoluble protein fraction was extracted by incubation with protein sample buffer and scraping the plate. Protein content was determined for the soluble fraction and equal volumes were loaded from both fractions.
Lactate assay Cells were incubated in fresh medium at 24-48 h following transfection with the indicated plasmids or at 72 h following transfection with siRNA. Lactate levels in the medium following incubation as well as baseline levels in fresh medium were determined using colorimetric Lactate assay kit (BioVision, Mountain View, CA, USA). Cells were harvested and total protein level in each well was determined using the Bradford assay (Bio-Rad); these were used to normalize lactate production to cell mass.
Glucose uptake Transfected cells were incubated for 2 h in normoxic conditions with fresh Dulbecco's modified Eagle medium containing 5.5 mM glucose (Biological Industries) without serum to reduce competition on the glucose transporter. A medium aliquot was removed for lactate assay and cells were incubated with 100 mM of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (Invitrogen, Carlsbad, CA, USA) for 30 min. Medium was removed, cells were washed once with PBS and suspended by trypsinization. Trypsinization was stopped by addition of cold Dulbecco's modified Eagle medium with serum. Cells were maintained on ice and promptly assayed by flow cytometry. Cells not incubated with 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose were used to determine background fluorescence. FACSAriaII flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) was used to collect data from 10 000 single cell events for each sample.
In vitro kinase assay HEK293T cells were transiently transfected with GFP-PKM2. Cells were harvested after 24 h and lysed in B-buffer supplemented with protease inhibitors and phosphatase inhibitors (1 mM NaF and 50 mM b-glycerolphosphate). GFP-PKM2 was immunoprecipitated with anti-GFP antibodies bound to protein G agarose beads. Beads were washed with supplemented B-buffer and pelleted. Increasing amounts of GFP-PKM2-loaded beads were incubated with equal amount of purified FLAG-DAPk for 30 min at 30 1C in kinase buffer (50 mM Hepes, pH 7.5, 20 mM MgCl 2 ) supplemented with 0.16 mCi/ml[g-33 P]ATP, 50 mM ATP, 1 mM bovine calmodulin and 0.5 mM CaCl 2 . Purified MCM3 (Bialik et al., 2008) incubated with DAPk served as positive control.
Cell proliferation measurements HEK293T cells were harvested 24 h after transfection with DAPkDKD or irrelevant protein and re-plated in equal numbers in triplicates. Cells were harvested after 48 h, stained with trypan blue and counted with an automated cell counter (Countess, Invitrogen) to determine total cell count, and live and dead cell counts. Population doubling time (PDT) was calculated according to the equation (Spoden et al., 2008) :
PDT ¼ time Â logð2Þ logðfinal cell countÞ À logðinitial cell countÞ
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